Abstracts tagged "Lupus"

Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1611 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?
Jennifer Lofland¹, Eric Wan ², Pamela Berry ³ and Chetan Karyekar ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Johns Hopkins Bloomberg School of Public Health, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Global Services, LLC, Horsham, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that causes connective tissue inflammation and can result in multiple organ damage. Registries may be…
Abstract Number: 2530 • 2019 ACR/ARP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Ben Snyder ¹, Darrin Bomba ², Ken Harvey ², Janet Anderl ², Christopher Kirk ², Jinhai Wang ², R Andrea Fan ² and Niti Goel³, ¹Nucleus Network Pty Ltd, Melbourne, Australia, ²Kezar Life Sciences, SOUTH SAN FRANCISCO, CA, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616, a first-in-class selective inhibitor of the immunoproteasome, is being evaluated for the treatment of multiple autoimmune diseases, including LN and PM/DM. At 30…
Abstract Number: 81 • 2019 ACR/ARP Annual Meeting
UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury
Sladjana Skopelja-Gardner¹, Joyce Tai ², Xizhang Sun ², Lena Tanaka ², Payton Hermanson ² and Keith Elkon ², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Sensitivity to ultraviolet B (UVB) light affects ~70% of SLE patients and exacerbates both skin disease and systemic flares, including lupus nephritis (LN). Our…
Abstract Number: 1022 • 2019 ACR/ARP Annual Meeting
Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages
Amrutesh Puranik¹, Yogita Ghodke-Puranik ², Regine Tipon ², Mark Jensen ¹, Auroni Gupta ³, Jacqueline Paredes ³, Uma Sankaramanchi ⁴, Ilona Nln ³, Amit Saxena ⁵, H. Michael Belmont ⁶, Peter Izmirly ⁷, Robert Clancy ⁷, Jill Buyon ⁵ and Timothy Niewold ², ¹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, ³Colton Center for Autoimmunity, NYU School of Medicine, ny, ⁴Colton Center for Autoimmunity, NYU Langone Medical Center, NY, ⁵New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, Ney York, ⁷New York University School of Medicine, New York
Background/Purpose: Both plasmacytoid dendritic cells (pDCs) and switched memory B cells (SMBCs) are considered to be key effector cells in systemic lupus erythematosus. It seems…
Abstract Number: 1613 • 2019 ACR/ARP Annual Meeting
LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis
Ji-Hyoun Kang¹, Seong-Eun Choi ¹, Haimuzi Xu ¹, Dong-Jin Park ¹ and Shin-Seok Lee ², ¹Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ²Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: There are few data on the effect of dyslipidemia in patients with lupus nephritis (LN). Thus, we investigated the effect of low-density lipoprotein-cholesterol (LDL-C)…
Abstract Number: 2550 • 2019 ACR/ARP Annual Meeting
Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study
Hayley Walter¹, Trevor Faith ², Alexander Alekseyenko ³, Ali Bakhtiari ³, Paula Ramos ² and Diane Kamen ⁴, ¹Division of Rheumatology/Medical University South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic and often severe multi-organ autoimmune disease characterized by the production of autoantibodies and heterogeneous clinical manifestations. African…
Abstract Number: 168 • 2019 ACR/ARP Annual Meeting
Development and Usability Testing of Take Charge: An Email Series to Increase Knowledge of Self-Management Skills in People with Lupus
Karin Tse ¹, Lauren Metelski ¹, Reid Dossinger ¹, Mike Donnelly ¹ and Latifa Boyce¹, ¹Lupus Foundation of America, Washington, DC
Background/Purpose: Email may be a promising approach to expose people with lupus, especially newly diagnosed patients, to educational information, tools, and resources on lupus self-management…
Abstract Number: 1026 • 2019 ACR/ARP Annual Meeting
Interferon Lambda Promotes Age-Associated B Cells
Jennifer Barnas¹, Nida Meednu ¹, Andrew McDavid ¹, Jennifer Albrecht ¹, Christopher Richardson ¹, R. John Looney ² and Jennifer Anolik ¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Age-associated B cells (ABC), defined as CD11c+ T-bet+ or CD11c+CD21-, represent a subset of B lymphocytes that are increased in systemic lupus erythematosus (SLE)…
Abstract Number: 1617 • 2019 ACR/ARP Annual Meeting
Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus
Yevgeniya Gartshteyn¹, Adam Mor ², Laura Geraldino ², Teja Kapoor ², Tommy Chen ², Thierry Dervieux ³ and Anca Askanase ⁴, ¹Columbia University School of Medicine, Glen Rock, NJ, ²Columbia University School of Medicine, New York, NY, ³Exagen, Vista, CA, ⁴Columbia University, New York
Background/Purpose: Cell-bound complement activation products (CB-CAPs), including platelet bound C4d (PC4d), are sensitive markers for diagnosis and evaluation of lupus activity. Presence of PC4d is…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 244 • 2019 ACR/ARP Annual Meeting
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: SLE is an autoimmune multi-system disease characterized by flares and more rarely remissions. Emerging biologic therapies for SLE are expected to change the treatment…
Abstract Number: 1036 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery
Nicholas Young¹, Kyle Jablonski ², Ifeoma Okafor ³, Emily Schwarz ³, Peter Harb ³, Caitlin Henry ³, Lai-Chu Wu ³ and Wael Jarjour ⁴, ¹The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Studies examining intracellular micro-RNA (miR) expression in PBMCs of patients with Systemic Lupus Erythematous (SLE) have identified distinct disease-associated changes in expression. We have…
Abstract Number: 1618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity
Diane Apostolopoulos¹, Rangi Kandane-Rathnayake ¹, Worawit Louthrenoo ², Shue Fen Luo ³, Yeong-Jian Wu ³, Aisha Lateef ⁴, Vera Golder ¹, Sargunan Sockalingam ⁵, Sandra Navarra ⁶, Leonid Zamora ⁷, Laniyati Hamijoyo ⁸, Yasuhiro Katsumata ⁹, Masayoshi Harigai ⁹, Madelynn Chan ¹⁰, Sean O'Neill ¹¹, Fiona Goldblatt ¹², Chak Sing Lau ¹³, Alberta Hoi ¹⁴, Mandana Nikpour ¹⁵ and Eric Morand ¹⁶, ¹Monash University, Melbourne, Australia, ²Chiang Mai University Hospital, Chiang Mai, Thailand, ³Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁴National University Hospital, Singapore, Singapore, ⁵University of Malaya, Kuala Lumpur, Malaysia, ⁶University of Santo Tomas Hospital, Manila, Philippines, ⁷Santo Tomas Hospital, Manila, Philippines, ⁸Padjadjaran University, Bandung, Indonesia, ⁹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹University of NSW, Ingham Institute of Applied Medical Research, Sydney, Australia, ¹²Royal Adelaide Hospital, Adelaide, Australia, ¹³Hong Kong University, Hong Kong, Hong Kong, ¹⁴School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁵St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, ¹⁶Monash University, Melbourne, Victoria, Australia
Background/Purpose: Accrual of irreversible organ damage is a major risk factor for death in SLE. While unmodifiable factors, such as age at disease onset and…
Abstract Number: 2564 • 2019 ACR/ARP Annual Meeting
Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Ji-Hyoun Kang¹, Seong-Eun Choi ¹, Haimuzi Xu ¹, Dong-Jin Park ¹ and Shin-Seok Lee ², ¹Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ²Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].